PHP 201
Alternative Names: AMA-0076; PHP-201Latest Information Update: 04 May 2021
At a glance
- Originator Amakem
- Developer Amakem; pH Pharma
- Class Antiglaucomas; Benzoates
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glaucoma; Low tension glaucoma; Ocular hypertension
Most Recent Events
- 29 Apr 2021 pH Pharma plans a phase III trial for Glaucoma and Ocular hypertension in South Korea (Ophthalmic) in November 2021 (NCT04863365)
- 28 Mar 2021 No recent reports of development identified for phase-I development in Glaucoma(In volunteers) in South Korea (Ophthalmic, Drops)
- 02 May 2018 pH Pharma completes a phase II trial for Low tension glaucoma in South Korea (NCT03106532)